TMCnet News
ENTEROMEDICS INC FILES (8-K) Disclosing Change in Directors or Principal Officers, Financial Statements and Exhibits(Edgar Glimpses Via Acquire Media NewsEdge) Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On October 30, 2014, EnteroMedics Inc. (the "Company") announced that Brad Hancock would join the Company as Chief Commercial Officer ("CCO"), effective November 17, 2014. The Company announced Mr. Hancock's appointment in a press release issued on October 30, 2014. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. Since 2012, Mr. Hancock, 57, has served as Vice President of Sales and Marketing at Flowonix Medical Inc., a company focused on implantable devices and techniques for improving drug delivery. From 2008 through 2012, he was Vice President and General Manager of the International Neuromodulation Division at St. Jude Medical, Inc., a role in which he managed the sales, marketing, regulatory, clinical, reimbursement, and financial functions for spinal cord and deep brain stimulation therapies. Prior to working at St. Jude Medical, Mr. Hancock had spent almost 20 years at Medtronic, Inc., holding sales management positions of increasing seniority in Medtronic's neuromodulation, spine, pain management, cardiac rhythm management and peripheral vascular divisions, serving most recently as Vice President of US Sales, Neuromodulation. Mr. Hancock began his career in the medical device field at Johnson and Johnson, where he held sales and sales management positions from 1982 to 1989. Mr. Hancock holds a B.S. in Business Administration from Miami University. There are no arrangements or understandings between Mr. Hancock and any other person pursuant to which Mr. Hancock was appointed as CCO of the Company. Mr. Hancock does not have a direct or indirect material interest in any currently proposed transaction to which the Company is a party, nor has Mr. Hancock had a direct or indirect material interest in any such transaction since the beginning of the Company's fiscal year. Mr. Hancock has no family relationship with any other officer or director of the Company. Neither Mr. Hancock nor any immediate family member of Mr. Hancock has a material interest in any transaction with the Company involving the payment or receipt of at least $120,000. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press release of EnteroMedics Inc. dated October 30, 2014. -------------------------------------------------------------------------------- |